# A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

> **NCT02593162** · PHASE2 · COMPLETED · sponsor: **Trek Therapeutics, PBC** · enrollment: 16 (actual)

## Conditions studied

- Hepatitis C Viral Infection
- Chronic Hepatitis C
- Hepatitis C (HCV)
- Hepatitis C Genotype 4

## Interventions

- **DRUG:** Faldaprevir
- **DRUG:** TD-6450
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02593162
- **Lead sponsor:** Trek Therapeutics, PBC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02593162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02593162, "A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02593162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*